Compare BioNTech SE - ADR (BNTX) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Devon Energy Corp — how do they compare? BioNTech SE - ADR trades at $92.59 (market cap $23.31B), while Devon Energy Corp trades at $45.26 (market cap $49.94B). The key difference: Devon Energy Corp is far larger — about 2.1× BioNTech SE - ADR's market cap, and Devon Energy Corp pays a 2.82% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | DVN | |
|---|---|---|
Market Cap | $23.31B | $49.94B |
Sector | Health | Energy |
52-Week High | $119.34 | $52.07 |
52-Week Low | $83.89 | $31.74 |
Enterprise Value | $6.60B | $60.68B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Devon Energy (DVN) trades at $45.36, up 5.54% with strong technical momentum and bullish analyst sentiment. The company delivered robust Q2 2026 results, beating EPS estimates by 21% and revenue by 18%, while raising dividends 33% and accelerating debt reduction. Valuation remains attractive with P/E of 9.87 and EV/EBITDA of 6.89, supported by $1.7B Q2 free cash flow and $8B buyback authorization.
Outlook remains positive with merger synergies tracking ahead of schedule and 2026 revenue guidance of $19.7B. Key risks include oil price volatility and integration execution from the Coterra merger. With 71% analyst buy ratings and $61.91 consensus target representing 36% upside, DVN offers compelling value for energy investors seeking growth and shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
